Security record · archived quarter
KMDA
Kamada Ltd. · Healthcare · Drug Manufacturers - Specialty & Generic
4Tracked holders
0Δ holders
1.28MShares held
$6.90MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 27 | +5 | 2.57M | $19.13M | +6 | −1 |
| Q1 2026 | 22 | -3 | 2.50M | $509.41M | +1 | −4 |
| Q4 2025 | 25 | -1 | 2.61M | $442.17M | — | −1 |
| Q3 2025 | 12 | 0 | 1.99M | $13.83M | — | — |
| Q2 2025 | 9 | +2 | 1.71M | $13.25M | +2 | — |
| Q1 2025 | 6 | +2 | 1.56M | $10.32M | +2 | — |
| Q4 2024 | 4 | 0 | 1.20M | $7.32M | — | — |
| Q3 2024 | 4 | 0 | 1.28M | $6.90M | — | — |
| Q2 2024 | 4 | — | 993.01K | $4.93M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 856.11K | +2.4% | $4.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Millennium Management ✦ | 354.78K | +252.9% | $1.91M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 46.13K | +52.2% | $247,713 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 46.13K | +52.2% | $247,713 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 27.74K | +7.2% | $148,963 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 41 holders, 5.10M shares, $528.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API